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Abstract
The clinical-high-risk for psychosis (CHR-P) syndrome is heterogeneous in terms of clinical 
presentation and outcomes. Identifying more homogenous subtypes of the syndrome may help 
Corresponding Author: Arthur T. Ryan, 36 Eagle Row, #270, Atlanta GA 30307, Tel: 404-727-7547, Fax: 404-727-1284, 
arthur.t.ryan@gmail.com. 
Conflict of Interest
There are no conflicts of interest for any of the authors with respect to the data in this paper or for the study.
Contributors
Dr. Arthur Ryan undertook the statistical analysis and wrote the first draft of the manuscript. Dr. Elaine Walker was involved in the 
writing of subsequent drafts of the manuscript. All of the authors listed were involved in study design and have contributed to and 
approved the final manuscript.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Schizophr Res. Author manuscript; available in PMC 2019 June 23.Author M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
clarify its etiology and improve the prediction of psychotic illness. This study applied latent class 
cluster analysis (LCCA) to symptom ratings from the North American Prodrome Longitudinal 
Studies 1 and 2 (NAPLS 1 and 2). These analyses produced evidence for three to five subgroups 
within the CHR-P syndrome. Differences in negative and disorganized symptoms distinguished 
amongst the subgroups. Subgroup membership was found to predict conversion to psychosis. The 
authors contrast the methods employed within this study with previous attempts to identify more 
homogenous subgroups of CHR-P individuals and discuss how these results could be tested in 
future samples of CHR-P individuals.
Keywords
Schizophrenia; Prodrome; Finite Mixture Models; Disorganization Symptoms; Heterogeneity
1 Introduction
Individuals with the clinical high risk for psychosis (CHR-P) syndrome (also known as the 
psychosis prodrome, schizophrenia prodrome, and ultra-high-risk syndrome) have a 17–25% 
chance of developing a psychotic illness within two years (Fusar-Poli et al., 2016). However, 
symptoms and outcomes among CHR-P individuals are highly heterogeneous (Fusar-Poli, 
2017). Identifying more homogenous phenotypic subgroups within the CHR-P syndrome 
may aid in clarifying prognosis, etiology, and response to treatment (Compton et al., 2014).
Valmaggia et al. (2013) applied a latent class cluster analysis (LCCA) to Comprehensive 
Assessment of At-Risk Mental State (CAARMS) symptom ratings (Yung et al., 2005) of 
CHR-P participants to identify more homogenous subgroups of CHR-P individuals on the 
basis of symptom configurations. Their analysis identified four subgroups that varied 
primarily in terms of symptom severity. Subgroup membership predicted important clinical 
outcomes, such as rates of conversion to psychotic illness.
In the current study, we apply LCCA to identify subgroups based on symptom ratings from 
the Structured Interview of Prodromal Symptoms (SIPS) and its companion rating scale, the 
Scale of Prodromal Symptoms (Miller et al., 2003). Conducting an analysis similar to the 
one conducted by Valmaggia et al. has several important functions. Such an analysis can 
determine differences between the SIPS and the CAARMS result in different clustering 
solutions. While similar, both the SIPS and CAARMS assess content areas not measured by 
the other. The SIPS and CAARMS also divide up symptomatology differently amongst their 
respective symptom rating scales. See Table 1 for a comparison of the symptoms assessed by 
the CAARMS and SIPS. If a similar cluster structure emerges from the current analysis, this 
would suggest that the overlapping content of the SIPS and CAARMS is sufficient to 
identify the same CHR-P subgroups. Contrastingly, if a different subgroup structure 
emerges, this would suggest that differences between the SIPS and CAARMS may prevent 
the identification of one or more of the subgroups identified by the other instrument. A 
failure of our LCCA to replicate Valmaggia’s results might also suggest important 
differences regarding subject recruitment and other extraneous factors between our sample 
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and Valmaggia’s: some authors have cited such factors as a pervasive challenge to 
developing reliable subtyping strategies generally (Cornblatt et al., 2015).
The goals of this study were: (1) employ LCCA to attempt to identify subtypes/subgroups 
within the CHR-P syndrome on the basis of symptom ratings and (2) determine if the 
LCCA-derived subgroups differed in terms of their demographics, clinical symptoms, and 
rates of conversion to psychotic illness.
2 Methods
2.1 Sample Description
Data were collected as part of the first and second iteration of the North American Prodrome 
Longitudinal Study: NAPLS 1 and NAPLS 2 (Addington et al., 2012, 2007). Detailed 
information regarding the samples can be found in the referenced papers. Both studies 
admitted individuals who met criteria for any of three risk syndromes: attenuated positive 
symptoms (APS), genetic risk and deterioration (GRD), and brief intermittent psychotic 
symptoms (BIPS). Analyses for this study were restricted to the 356 NAPLS 1 and 737 
NAPLS 2 CHR-P subjects who had complete baseline symptom data. One difference 
between the NAPLS 1 and 2 recruitment criteria was that NAPLS 2 added an additional 
CHR-P syndrome: being younger than 18-years-old and having a diagnosis of schizotypal 
personality disorder (YSPD). Nine percent of the NAPLS 2 sample met criteria for YSPD, 
but only 18 individuals (2.4% of the NAPLS 2 CHR-P sample) met criteria solely for YSPD. 
The demographics of the NAPLS 1 and 2 samples are shown in Table 2. All procedures were 
approved by the Institutional Review Board (IRB) at each site. Written informed consent 
(with assent from participants younger than 18) was obtained from all participants.
2.2 Clinical Measures
CHR-P symptoms were assessed using the Structured Interview for Prodromal Syndromes 
(SIPS) and its companion scale, the Scale of Prodromal Symptoms (Miller et al., 2003). 
Nineteen SIPS symptom items are rated 0–6 based on their severity and those items are 
categorized into four domains (positive, negative, disorganized, and general). These domains 
were modeled after the ones set out by Yung et al. in the CAARMS (Fusar-Poli et al., 2017). 
Medication history was assessed with a lifetime medication history interview. Individual 
medications had only been coded into distinct classes and divided between lifetime and 
current use for the NAPLS 2 dataset, so psychotropic medication history analyses were 
restricted to the NAPLS 2 dataset. Demographic data were collected using a demographics 
interview.
2.3 Statistical Analysis
Statistical analyses were performed using R version 3.3.1 (R Core Team, 2016) 
supplemented with the mclust package (Fraley et al., 2012; Fraley and Raftery, 2002). The 
mclust package implements latent class cluster analysis (LCCA) by attempting to identify a 
best fitting Gaussian finite mixture model—i.e., the one with the lowest Bayesian 
information criterion (BIC) value—using an expectation-maximization (EM) algorithm. 
Separate LCCAs were computed for the NAPLS 1 and 2 samples. ANOVA tests, χ2 tests, 
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and Kaplan-Meir survival analyses were conducted to compare the LCCA-derived 
subgroups on relevant variables and any significant tests were followed up with pairwise 
comparisons. SPSS 17 was used for ANOVA and χ2 analyses.
3 Results
3.1 NAPLS 1 and 2 Sample Comparisons
Demographic and SIPS syndrome information for the NAPLS 1 and 2 samples are shown in 
Table 2. The samples differed significantly in race (χ2 = 50.916, df =6, p < .001): pairwise 
comparisons are shown in Table 2. NAPLS 1 had a greater proportion of individuals with 
APS (χ2 = 7.032, df =1, p < .01), although this difference was not large in absolute terms 
(96% APS prevalence in NAPLS 1 vs. 92% in NAPLS 2).
3.2 NAPLS 1 LCAA
A LCCA analysis of the NAPLS 1 baseline SIPS data identified an ellipsoidal, equal volume 
and orientation (EVE) Gaussian distribution with three classes as the best fitting model (log. 
likelihood = −10753, n = 356, df = 285, BIC = 23181, clustering table = 40/108/208). The 
normalized entropy value was 0.93, suggesting the model was a good fit for the data. The 
first subgroup was distinguished by its large size (58% of the total sample), the presence of 
perceptual abnormalities, and low levels of negative, disorganized, and general symptoms. 
This subgroup was labeled the Perceptual Abnormalities Subgroup (PAS). The second 
subgroup (30% of the total sample) was distinguished by elevated negative symptoms, 
disorganized speech, other disorganization symptoms, and general symptoms. We labeled 
this group the Disorganized Speech Subgroup (DSS). The third subgroup (11% of the total 
sample) was distinguished by hygiene impairment without marked disorganized speech. We 
labeled this group the Impaired Hygiene Subgroup (IHS).
Demographic and clinical measures of the NAPLS 1 subgroups are summarized in Table 3. 
ANOVAs and χ2 tests showed that the subgroups did not differ significantly on any of the 
demographic variables with the exception of gender (χ2 = 6.749, df = 2, p < .05). Pairwise 
comparisons showed that PAS individuals were more likely to be female than IHS 
individuals (p < .05).χ2 tests of the SIPS syndrome categories showed a significant 
difference between the subgroups in the prevalence of GRD (χ2 = 29.567, df = 2, p < .001). 
Pairwise comparisons showed that GRD prevalence was higher in the DSS (p < .05). The 
time between CHR-P participants baseline assessment and final assessment was then 
examined. A minority of the NAPLS 1 sample (21.6%) had final follow-up times as far out 
as four years, far beyond the two-year timeline of the study. In order to ensure these outliers 
were not having an outsized influence on the analysis, the Kaplan-Meir survival analysis was 
run with and without a 2.5 year follow-up cut-off. The results were similar in both cases and 
the 2.5 year cut-off results are reported here for parity with the NAPLS 2 analysis below. 
The Kaplan-Meir survival curve comparing conversion rates across the subgroups was 
significant (Mantel-Cox χ2 = 8.104, df = 2, p < .05). A graph of the survival curves is shown 
in Figure 1. Mantel-Cox pairwise comparisons showed that the DSS had a higher conversion 
rate than the PAS (χ2 = 7.290, df = 1, p < .01). There was a trend towards the DSS having a 
higher conversion rate than the IHS (χ2 = 2.759, df = 1, p = .097). The results of ANOVAs 
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comparing the subgroups’ symptom ratings are shown in Table 4. The subgroup symptom 
means are also shown as a line graph in Figure 2.
3.3 NAPLS 2 LCCA
A LCCA analysis of the NAPLS 2 baseline SIPS data identified an EVE Gaussian 
distribution with five classes as the best fitting model (log. likelihood = −22103.56, N = 737, 
df = 361, BIC = 46590, clustering table = 120/134/40/30/413). The normalized entropy 
value was 0.82, suggesting that the model was a good fit for the data. When the five 
subgroup solution was examined, it was found that the three largest subgroups cumulatively 
comprised 91% of the sample, with the two additional subgroups making up 5% and 4% of 
the sample respectively. The symptom ratings and relative frequencies of the three largest 
subgroups resembled those found in the NAPLS 1 model. The larger of the two new 
subgroups was labeled the Odd and Euthymic Subgroup (OES) because of its low ratings on 
scales of distress and psychopathology, along with elevated ratings of odd behavior and 
thought. The second additional subgroup was labeled the Distressed and Avolitional 
Subgroup (DAS) due to its high ratings of distress and impairment, which contrasted with its 
uniquely low positive symptom ratings.
Demographic and clinical variables for the NAPLS 2 subgroups are summarized in Table 5. 
ANOVA and χ2 tests showed that the subgroups did not differ significantly on any of the 
demographic variables with the exception of mother’s education [F (4, 719) = 4.521, p = .
01]. The mothers of DSS and OES individuals were more likely to have completed college 
than the mothers of PAS participants (p < .05). χ2 tests of the SIPS syndrome categories 
showed a significant difference between the subgroups in the prevalence of APS (χ2 = 
15.612, df = 4, p < .01), GRD (χ2 = 21.397, df = 4, p < .001), and YSPD (χ2 = 25.924, df = 
4, p < .001). Significant pairwise comparisons are shown in Table 5. Similarly to the NAPLS 
1 cohort, when the time between baseline assessment and final assessment was examined, a 
minority of the NAPLS 2 cohort had follow-up dates up to four years after their baseline 
assessment. However, only 3% (n = 18) of the NAPLS 2 sample had final assessments 
greater than 2.5 years after their baseline, so this small group of outliers was simply 
excluded before running the analysis. A Kaplan-Meir survival curve comparing conversion 
rates across the subgroups was significant (Mantel-Cox χ2 = 11.062, df = 4, p < .05). 
Mantel-Cox pairwise comparisons showed that DSS individuals were more likely to convert 
over time than PAS individuals (χ2 = 9.105, df = 1, p < .01). There was a trend towards DSS 
individuals being more likely to convert over time than IHS individuals (χ2 = 3.620, df = 1, 
p = .057) and OES individuals (χ2 = 3.104, df = 1, p = .078). The survival curve is shown in 
Figure 3. The results of ANOVAs comparing the subgroups’ symptom ratings are shown in 
Table 6. The subgroup symptom means are also shown as a line graph in Figure 4.
The NAPLS 2 subgroups were additionally compared in terms of lifetime and baseline 
medication treatment with the following medication classes: antidepressant, mood stabilizer, 
antipsychotic, stimulant, benzodiazepine, and any psychotropic medication. The only 
significant χ2 test was for lifetime mood stabilizer use (χ2 = 17.795, df =4, p < .001). 
Pairwise comparisons are shown in Table 5.
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4 Discussion
This paper describes the results of latent class cluster analyses (LCCAs) to identify 
subgroups of the clinical high risk for psychosis (CHR-P) syndrome based on SIPS 
symptom ratings. These analyses produced statistical support for the existence of three 
subgroups within the NAPLS 1 and NAPLS 2 samples: a Perceptual Abnormalities 
Subgroup (PAS), Disorganized Speech Subgroup (DSS), and Impaired Hygiene Subgroup 
(IHS). Two additional low-frequency subgroups were found in the NAPLS 2 sample, the 
Odd and Euthymic Subgroup (OES) and the Distressed and Avolitional Subgroup (DAS).
4.1 Comparisons Between This Study and Previous Attempts to Identify Homogenous 
CHR-P Subgroups
The LCCAs described here differ in some significant ways from previous attempts to 
identify homogenous subgroups of CHR-P individuals. Fusar-Poli and colleagues (2016) 
conducted a meta-analysis to determine whether different CHR-P syndromes—i.e., 
Attenuated Positive Symptoms (APS), Genetic Risk and Deterioration (GRD), and Brief 
Intermittent Psychotic Symptoms (BIPS) syndromes—have different rates of conversion to 
psychosis. Fusar-Poli et al. concluded that BIPS individuals did indeed appear to have an 
increased rate of conversion to psychosis and that GRD individuals did not appear to differ 
from individuals who did not meet criteria for CHR-P. In contrast to Fusar-Poli et al.’s 
findings, we found that LCCA-derived subgroups were not differentiated by the prevalence 
of BIPS. Also, the NAPLS 1 and 2 LCCA subgroup with the highest rate of conversion, the 
DSS, had the highest prevalence of GRD. This suggests that previously defined CHR-P 
syndromes may themselves be heterogenous categories and not represent natural divisions 
within the CHR-P syndrome.
In another attempt to identify homogenous subgroups of CHR-P individuals, Cornblatt and 
colleagues (2015) restricted their CHR-P sample to only those who met criteria for APS. 
While they were able to identify a model that predicted conversion accurately in their 
study’s sample, their model was not predictive when applied to a similarly selected sample 
(Addington et al., 2017). Cornblatt et al.’s results suggest that more restrictive recruitment 
criteria may not be sufficient for identifying more homogenous subgroups of CHR-P 
individuals.
Several of the previous attempts to identify more homogenous CHR-P individuals have 
adopted a “staging model” framework, meaning they assumed that different subgroups 
represent points along a risk continuum for psychosis (Carrión et al., 2017). In contrast to 
this, the models described here do not make the assumption that the LCCA derived 
subgroups represent different points along a risk continuum. In this way, the current project 
more closely resembles work like that of the Bipolar-Schizophrenia Network for 
Intermediate Phenotypes (B-SNIPS) (Tamminga et al., 2014). Tamminga and colleagues 
purposefully collected their psychotic illness probands sample without regard to DSM-5 
(American Psychiatric Association, 2013) distinctions between bipolar, schizophrenia, and 
schizoaffective disorders. Instead, they employed machine learning techniques to identify 
homogenous subgroups on the basis of neurobiological markers (e.g., EEG measures and 
neuropsych testing). Their analyses yielded three “biotypes” that cut across the diagnostic 
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boundaries of the DSM. Most interestingly, these biotypes proved to have novel explanatory 
power that samples restricted to DSM-5 diagnoses would otherwise miss. Clementz and 
colleagues (2016) demonstrated that two of the biotypes had similar levels of impairment on 
tasks of attention despite having diametrically opposed deviations from normative EEG 
signatures. Clementz et al. proposed that such previously unidentified biotypes might 
underlie the contradictory findings that have bedeviled EEG research on psychotic disorders.
We should note that our findings were congruent with those of Cornblatt et al. (2015) and 
Addington et al. (2017) in several respects. Each study found that disorganization symptoms 
are an important marker for outcomes among CHR-P individuals. Our results are also 
consistent with previous studies that have shown that negative symptoms, (e.g., alogia and 
anhedonia) are important in predicting transition to psychosis (Valmaggia et al., 2013).
It is also important to compare the results of our analyses directly with those of previous 
LCCAs of CHR-P individuals. Table 7 shows the CHR-P symptoms that best distinguished 
LCCA-derived subgroups in the NAPLS I, NAPLS II, Healey et al. (2017), and Valmaggia 
et al. (2013) analyses. The top seven most discriminative symptoms have been emphasized 
for each analysis. As can be seen, five of the top seven most informative symptoms were 
shared across the NAPLS 1 and 2 lists, while only one of those symptoms appeared on the 
Healey et al. list and two appeared on the Valmaggia et al. list. We believe that several 
factors lead to the greater similarity between the NAPLS 1 and 2 analyses. First, both 
analyses had larger subjects-to-parameters-ratio, which increases reliability. Second, the 
NAPLS samples were collected by several of the same sites (with some additional sites 
added in NAPLS 2) using similar protocols. Third, Healey et al. incorporated additional data 
sources (depression scores and neurocognitive testing) in their LCCA model. Finally, the 
Valmaggia et al. sample differed in that symptoms were measured using the CAARMS.
Some specific differences between our analyses and those conducted by Healey et al should 
be noted. Healey et al. combined CHR-P individuals with help-seeking controls (who 
generally met sub-threshold versions of CHR-P criteria) in their LCCA. This was an 
understandable choice, both to increase their sample size and because of their interest in 
determining whether these relaxed criteria still identified individuals at risk for psychosis. In 
practice, however, this choice meant that only 171 CHR individuals were used to estimate 
106, 133, and 160 different parameter values for their three, four, and five class LCCA’s 
respectively (see Table 1 in Healy et al. 2017). Such low subjects-to-estimated-parameters 
ratios are likely to produce unstable solutions (Dolnicar, 2002). Healey et al. also included 
several measures other than SIPS symptom ratings into their LCCA model (i.e., depression 
symptom ratings and neurocognitive testing). While such rich data brings the possibility of 
identifying novel subgroups, additional data is not necessarily useful for identifying 
meaningful clinical subgroups. For example, research into atypical depression has shown 
that the single symptom of increased appetite provides excellent discrimination of this 
depression subtype (Milaneschi et al., 2016).
Comparing our results to those of Valmaggia and colleagues (2013) is of particular 
importance, as Valmaggia et al.’s work represents, to our knowledge, the largest sample used 
for a LCCA of CHR-P symptom ratings prior to our own. While Valmaggia et al. 
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emphasized the importance of negative and disorganization symptoms in differentiating their 
subgroups, the individual symptom that best differentiated their subgroups was “subjective 
motor functioning,” whose R2 effect size was a remarkable .94 (see Table 4 in Valmaggia et 
al. 2013 and Table 7 in this paper). This is an interesting finding for several reasons. Motor 
functioning deficits have been shown to be an informative biomarker for psychotic illness 
(Schiffman, 2017). Secondly, the SIPS does not have an item which corresponds to 
subjective motor functioning (Miller et al., 2003). The SIPS “motor impairment” item is 
rated on a combination of reported/observed motor deficits and reported/observed abnormal 
movements. Perhaps due to this fact, the corresponding SIPS item was not nearly as 
discriminative in the NAPLS 1 and 2 LCCAs. It should be noted that our analyses of the 
NAPLS samples yielded a similarly, though not quite as, informative symptom rating, 
namely “impairment in personal hygiene,” whose η2 values were .67 and .66 in the NAPLS 
1 and 2 LCCAs respectively. Valmaggia’s finding regarding subjective motor impairment in 
the context of ours regarding hygiene impairment demonstrates some of the promise of 
LCCA and similar techniques. It shows that seemingly minor differences in the content 
coverage of the SIPS and CAARMS may possibly have a significant impact on their ability 
to detect underlying subtypes of the CHR-P syndrome.
A few additional specific differences between our LCCAs and Valmaggia et al.’s bear 
mentioning: (a) Valmaggia et al.’s high-risk subtype composed only approximately 6% of 
their sample (17 individuals) while the DSS composed 30% and 18% of the NAPLS 1 and 2 
samples respectively, (b) our subgroups were not best characterized as a stepwise pattern of 
symptom severity, (c) our subgroups did not vary in age, (d) Valmaggia et al.’s subgroups 
were not differentiated by disorganized speech, other than in so far as their mild subgroup 
had lower levels than their other subgroups.
While the differences between Valmaggia et al.’s findings and our own are interesting, the 
parallels are also important. Four of the seven most informative symptoms in Valmaggia et 
al.’s analysis were also among the most informative in either the NAPLS 1 or 2 LCCA (see 
Table 7). In line with Valmaggia et al.’s discussion of their findings, these most informative 
symptoms were negative and cognitive symptoms.
4.2 Ideas for Future Testing of Putative CHR-P Subtypes and Conclusion
Narrative descriptions of similarities and differences between clustering solutions are not a 
conclusive method for generalizing our findings. We propose that the analyses presented 
here are a first step towards attempts to validate our findings in future datasets. One way that 
this work could be continued is by attempting to replicate the results of our LCCA analysis 
in a new sample by applying the weights of our LCCA models to other samples and 
checking if they still accurately characterize the data. Perhaps even more interestingly, one 
could apply a random forest analysis (Breiman, 2001) to identify a human-interpretable set 
of binary questions (i.e., a decision tree algorithm) that could be used to assign CHR-P 
individuals to subgroups on the basis of their SIPS symptom ratings. For an example of an 
application of decision tree algorithms in suicide research, see Kessler et al., 2017. Once 
CHR-P individuals have been classified into LCCA-derived subgroups, investigators may 
then determine whether those subgroups have similar charecteristics to the ones found in our 
Ryan et al. Page 8
Schizophr Res. Author manuscript; available in PMC 2019 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
NAPLS LCCA-derived subgroups (e.g., that individuals identified as DSS indeed have the 
highest rate of conversion, etc.).
It is important to note several important limitations of our study. We were not able to directly 
test existing LCCA models of CHR-P symptoms, such as the ones described by Valmaggia 
et al. (2013) or Healey et al. (2017). In the case of Valmaggia et al., this could not be done 
given their use of the CAARMS. In regards to Healey et al., we could not apply their LCCA 
solution to our own data as they included neuropsychological testing and depression 
symptom ratings in their clustering solution. In contrast, we specifically sought to see what 
subgroups (if any) could be identified on the basis of SIPS ratings alone. Second, our 
analyses of conversion rates were hampered by the high rates of loss to follow-up in the 
NAPLS 1 and 2 datasets. However, the use of Kaplan-Meir survival analyses to account for 
data-censoring due to loss to follow-up helped to address this issue.
The work presented in this paper has several noteworthy strengths. To our knowledge, our 
analyses included the two largest samples of CHR-P symptom ratings used with LCCA to 
date. Second, our LCCA analyses on two separate datasets identified recognizably similar 
subgroup solutions. A third strength of our analysis is that the subgroups identified by our 
LCCAs did not differ primarily in terms of global symptom severity, but rather primarily on 
the basis of specific configurations of elevated symptoms (e.g., disorganized speech in the 
DSS). Fourth, our subgroups were not explicable terms of existing classification schemes of 
CHR-P (e.g., APS vs. BIPS).
This paper presents the results of a series of LCCAs to identify subgroups of CHR-P 
individuals using the NAPLS 1 and 2 datasets. These analyses evinced the existence of three 
to five subgroups which appear to differ meaningfully on clinical outcomes and other 
variables.
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Figure 1. NAPLS 1 Kaplan-Meir Survival Curve
This figure graphs the Kaplan-Meir survival curve for conversion to psychosis among the 
subgroups identified in the NAPLS 1 latent class cluster analysis.
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Figure 2. NAPLS 1 LCCA-Derived Subgroup Symptom Means
This line graph shows the mean symptom ratings for each of the subgroups identified in the 
NAPLS 1 latent class cluster analysis.
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Figure 3. NAPLS 2 Kaplan-Meir Survival Curve
This figure graphs the Kaplan-Meir survival curve for conversion to psychosis among the 
subgroups identified in the NAPLS 2 latent class cluster analysis.
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Figure 4. NAPLS 1 LCCA-Derived Subgroup Symptom Means
This line graph shows the mean symptom ratings for each of the subgroups identified in the 
NAPLS 1 latent class cluster analysis.
Ryan et al. Page 15
Schizophr Res. Author manuscript; available in PMC 2019 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ryan et al. Page 16
Ta
bl
e 
1
Co
m
pa
ris
on
 o
f S
IP
S 
an
d 
CA
A
RM
S 
Sy
m
pt
om
 S
ca
le
s
Sc
al
es
 w
ith
 a
 C
lo
se
 C
ou
nt
er
pa
rt
Sc
al
es
 W
ho
se
 C
on
te
nt
 is
 D
iv
id
ed
 D
iff
er
en
tly
o
r 
W
ith
 O
nl
y 
an
 A
pp
ro
x
im
at
e 
C
ou
nt
er
pa
rt
Sc
al
es
 W
ith
ou
t a
 C
le
ar
 C
ou
nt
er
pa
rt
SI
PS
C
A
A
R
M
S
SI
PS
C
A
A
R
M
S
SI
PS
C
A
A
R
M
S
•
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
•
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
•
U
nu
su
al
 Id
ea
s
•
Su
sp
ic
io
us
ne
ss
•
U
nu
su
al
 T
ho
ug
ht
 C
on
te
nt
•
Im
pa
irm
en
t i
n 
Pe
rs
on
al
 H
yg
ie
ne
•
D
iso
rg
an
iz
ed
 S
pe
ec
h
•
D
iso
rg
an
iz
ed
 S
pe
ec
h
•
Tr
o
u
bl
e 
w
ith
 F
o
cu
s 
an
d 
A
tte
nt
io
n
•
Su
bje
cti
v
e 
Co
gn
iti
v
e 
Ch
an
ge
s
•
O
bs
er
ve
d 
Co
gn
iti
v
e 
Ch
an
ge
s
•
B
iz
ar
re
 T
hi
nk
in
g
•
O
cc
up
at
io
na
l F
un
ct
io
ni
ng
•
Im
pa
ire
d 
ro
le
 fu
nc
tio
n
•
D
ec
re
as
ed
 E
xp
re
ss
io
n 
of
 
Em
ot
io
n
•
O
bs
er
ve
d 
Bl
un
te
d 
A
ffe
ct
•
Sl
ee
p 
D
ist
ur
ba
nc
e
•
Im
pa
ire
d 
To
le
ra
nc
e 
to
 
N
or
m
al
 S
tre
ss
•
To
le
ra
nc
e 
to
 n
or
m
al
 st
re
ss
•
D
ec
re
as
ed
 Id
ea
tio
na
l R
ic
hn
es
s
•
A
lo
gi
a
•
A
gg
re
ss
io
n
•
Av
o
lit
io
n
•
Av
o
lit
io
n/
ap
at
hy
•
So
ci
al
 A
nh
ed
on
ia
•
So
ci
al
 Is
ol
at
io
n
•
Su
bje
cti
v
e 
B
od
ily
 S
en
sa
tio
ns
•
D
ec
re
as
ed
 E
xp
er
ie
nc
e 
of
 
Em
ot
io
n
•
A
nh
ed
on
ia
•
Su
bje
cti
v
e 
Em
ot
io
na
l 
D
ist
ur
ba
nc
es
•
D
iss
oc
ia
tiv
e 
Sy
m
pt
om
s
•
Su
bje
cti
v
e 
A
ut
on
om
ic
 F
un
ct
io
ni
ng
•
M
ot
or
 D
ist
ur
ba
nc
e
•
O
bs
er
ve
d 
M
ot
or
 F
un
ct
io
ni
ng
•
Su
bje
cti
v
e 
M
ot
or
 
Fu
nc
tio
ni
ng
•
M
oo
d 
sw
in
gs
•
G
ra
nd
io
sit
y
•
M
an
ia
Schizophr Res. Author manuscript; available in PMC 2019 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ryan et al. Page 17
Sc
al
es
 w
ith
 a
 C
lo
se
 C
ou
nt
er
pa
rt
Sc
al
es
 W
ho
se
 C
on
te
nt
 is
 D
iv
id
ed
 D
iff
er
en
tly
o
r 
W
ith
 O
nl
y 
an
 A
pp
ro
x
im
at
e 
C
ou
nt
er
pa
rt
Sc
al
es
 W
ith
ou
t a
 C
le
ar
 C
ou
nt
er
pa
rt
SI
PS
C
A
A
R
M
S
SI
PS
C
A
A
R
M
S
SI
PS
C
A
A
R
M
S
•
D
ys
ph
or
ic
 M
oo
d
•
D
ep
re
ss
io
n
•
Su
ic
id
al
ity
 a
nd
 S
el
f-H
ar
m
•
A
nx
ie
ty
•
O
CD
•
O
dd
 b
eh
av
io
r o
r a
pp
ea
ra
nc
e
•
D
iso
rg
an
iz
ed
, O
dd
, 
St
ig
m
at
iz
in
g 
Be
ha
v
io
r
•
O
bs
er
ve
d 
in
ap
pr
op
ria
te
 a
ffe
ct
N
ot
e:
 N
o 
of
fic
ia
l m
et
ho
d 
ex
ist
s f
or
 li
nk
in
g 
th
e 
SI
PS
 a
nd
 C
A
A
RM
S 
sc
al
es
. T
hi
s l
ist
 o
f p
ro
po
se
d 
co
un
te
rp
ar
ts 
is 
su
bje
cti
v
e 
an
d 
fo
r i
llu
str
at
iv
e 
pu
rp
os
es
.
Schizophr Res. Author manuscript; available in PMC 2019 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ryan et al. Page 18
Table 2
Demographics of NAPLS 1 and NAPLS 2 Datasets
NAPLS I NAPLS II
N 356 737
Age (SD) 18.3 (4.7) 18.5 (4.3)
Father’s Education (SD) 6.3 (1.7) 6.2 (1.7)
Mother’s Education (SD) 6.4 (1.6) 6.3 (1.6)
% Latino 14% 18%
% Female 38% 43%
% Native American and First Nations*** 0% 2%†
% Asian*** 6% 8%
% Black*** 13% 16%
% Other*** NA# 5%
% White*** 71%† 57%
% Native Hawaiian and Pacific Islander*** 0% 0%
% Multiracial*** 9% 12%†
Converted 12% 13%
APS** 96%† 92%
GRD 11% 11%
BIPS 3% 3%
YSPD NA# 9%
**
= p < .01,
***
= p < .001,
†
= value significantly larger in group contrast
Note: APS, GRD, and BIPS do not add up to 100% as an individual may belong to multiple groups.
#
= “Other” was not an option for racial identity in NAPLS I and YSPD was not assessed as a diagnostic category in NAPLS 1. APS = Attenuated 
Psychosis Syndrome; GRD = Genetic Risk and Deterioration Syndrome; BIPS = Brief Intermittent Psychosis Syndrome; YSPD = Youth and 
Schizotypal Personality Disorder Syndrome
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Table 3
Demographics and Clinical Features by Subgroup for the LCCA of the NAPLS 1 Dataset
Perceptual Abnormalities 
Subgroup (A)
Disorganized Speech 
Subgroup (B)
Impaired Hygiene 
Subgroup (C) Total
N (% of total) 208 (58%) 108 (30%) 40 (11%) 356
% Female* 43%C 34% 23% 38%
Age 18.3 18.3 18.5 18.3
Father’s Education (SD)† 4.7 4.5 5.1 4.7 (2.0)
Mother’s Education (SD)† 4.8 4.6 4.9 4.8 (1.9)
% Latino 14% 14% 15% 14%
% Native American and First Nations 0% 0% 0% 0%
% Asian 5% 4% 3% 4%
% Black 12% 8% 0% 9%
% White 74% 80% 90% 77%
% Native Hawaiian and Pacific Islander 0% 0% 0% 0%
% Multiracial 9% 8% 8% 9%
APS 97% 95% 95% 96%
GRD*** 5% 26%A 11% 12%
BIPS 3% 3% 5% 3%
Conversion* 11% 17%A 8% 12%
*
= p < .05,
***
= p < .001
†
= Absolute values of father’s and mother’s education reported here differ from those shown in Table 2 as the Table 2 values were converted to the 
education score metric used in NAPLS 2.
Note: Letters next to a value indicate the subgroups which that value was significantly larger than according to post hoc uncorrected pairwise Z or 
T tests. Pairwise comparisons were only conducted when the omnibus ANOVA, χ2, or Kaplan-Meir test was significant.
APS = Attenuated Psychosis Syndrome; GRD = Genetic Risk and Deterioration Syndrome; BIPS = Brief Intermittent Psychotic Symptoms 
Syndrome
Schizophr Res. Author manuscript; available in PMC 2019 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ryan et al. Page 20
Ta
bl
e 
4
A
N
OV
A
 o
f t
he
 L
CC
A
-D
er
iv
ed
 N
A
PL
S 
1 
Su
bg
ro
up
s S
ym
pt
om
 R
at
in
gs
PA
S 
M
ea
n 
(S
D)
 (A
)
D
SS
 M
ea
n 
(S
D)
 (B
)
IH
S 
M
ea
n 
(S
D)
 (C
)
To
ta
l M
ea
n 
(S
D)
P
η2
U
nu
su
al
 Id
ea
s
3.
1 
(1.
5)
3.
2 
(1.
6)
3.
4 
(1.
4)
3.
2 
(1.
5)
=
.6
1
0.
00
Su
sp
ic
io
us
ne
ss
2.
9 
(1.
5)C
3.
1 
(1.
4)C
1.
9 
(1.
5)
2.
8 
(1.
5)
<
.0
01
0.
05
G
ra
nd
io
sit
y
1 
(1.
3)
1.
2 
(1.
4)
1.
7 
(1.
6)A
1.
1 
(1.
4)
=
.0
1
0.
02
U
nu
su
al
 P
er
ce
pt
ua
l E
xp
er
ie
nc
es
3.
1 
(1.
7)C
2.
9 
(1.
6)
2.
4 
(1.
8)
2.
9 
(1.
7)
<
.0
5
0.
02
D
iso
rg
an
iz
ed
 S
pe
ec
h
1.
5 
(1.
4)
2.
5 
(1.
4)A
 C
1.
8 
(1.
3)
1.
8 
(1.
4)
<
.0
01
0.
09
So
ci
al
 A
nh
ed
on
ia
1.
9 
(1.
8)
3.
6 
(1.
6)A
 C
2.
1 
(1.
9)
2.
5 
(1.
9)
<
.0
01
0.
16
Av
o
lit
io
n
1.
8 
(1.
6)
3.
6 
(1.
3)A
 C
1.
9 
(1.
7)
2.
3 
(1.
7)
<
.0
01
0.
24
D
ec
re
as
ed
 E
m
ot
io
na
l E
xp
re
ss
io
n
1.
1 
(1.
4)C
2.
5 
(1.
6)A
 C
0.
4 
(0.
7)
1.
4 
(1.
6)
<
.0
01
0.
22
D
ec
re
as
ed
 E
m
ot
io
na
l E
xp
er
ie
nc
e
1.
2 
(1.
6)C
2.
6 
(1.
6)A
 C
0.
1 
(0.
3)
1.
5 
(1.
7)
<
.0
01
0.
22
D
ec
re
as
ed
 Id
ea
tio
na
l R
ic
hn
es
s
1 
(1.
4)C
2 
(1.
5)A
 C
0.
5 
(0.
8)
1.
3 
(1.
5)
<
.0
01
0.
12
O
cc
up
at
io
na
l F
un
ct
io
ni
ng
2.
7 
(1.
9)
3.
9 
(1.
4)A
 C
3.
1 
(2)
3.
1 
(1.
9)
<
.0
01
0.
09
O
dd
 B
eh
av
io
r
1 
(1.
3)
2.
1 
(1.
5)A
1.
8 
(1.
3)A
1.
4 
(1.
4)
<
.0
01
0.
13
B
iz
ar
re
 T
hi
nk
in
g
1.
5 
(1.
5)
2.
1 
(1.
6)A
1.
9 
(1.
3)
1.
7 
(1.
5)
=
.0
01
0.
04
Tr
o
u
bl
e 
w
ith
 F
o
cu
s 
an
d 
A
tte
nt
io
n
2.
2 
(1.
4)
3.
1 
(1.
1)A
 C
2.
2 
(1.
3)
2.
5 
(1.
4)
<
.0
01
0.
09
Im
pa
irm
en
t i
n 
Pe
rs
on
al
 H
yg
ie
ne
0 
(0)
2.
2 
(1.
1)A
 C
1.
8 
(1.
2)A
0.
9 
(1.
3)
<
.0
01
0.
67
Sl
ee
p 
D
ist
ur
ba
nc
e
1.
9 
(1.
7)
2.
4 
(1.
7)A
1.
9 
(1.
6)
2 
(1.
7)
=
.0
2
0.
02
D
ys
ph
or
ic
 M
oo
d
2.
9 
(1.
7)
3.
7 
(1.
5)A
 C
2.
5 
(1.
9)
3.
1 
(1.
7)
<
.0
01
0.
06
M
ot
or
 D
ist
ur
ba
nc
es
0.
5 
(1)
1.
2 
(1.
4)A
 C
0.
6 
(1.
3)
0.
7 
(1.
2)
<
.0
01
0.
06
Im
pa
ire
d 
To
le
ra
nc
e 
to
 N
or
m
al
 S
tre
ss
1.
9 
(1.
7)
3 
(1.
7)A
 C
1.
5 
(1.
4)
2.
2 
(1.
7)
<
.0
01
0.
09
N
ot
e:
 G
re
y 
lin
es
 se
pa
ra
te
 p
os
iti
v
e 
do
m
ai
n 
sc
or
es
, n
eg
at
iv
e 
do
m
ai
n 
sc
or
es
, d
iso
rg
an
iz
ed
 d
om
ai
n 
sc
or
es
, a
nd
 g
en
er
al
 d
om
ai
n 
sc
or
es
 re
sp
ec
tiv
el
y.
 
Le
tte
rs
 in
di
ca
te
 th
e 
ot
he
r s
ub
gr
ou
ps
 th
at
 w
er
e 
lo
w
er
 o
n
 th
e 
in
di
ca
te
d 
sy
m
pt
om
. P
ai
rw
ise
 c
om
pa
ris
on
s w
er
e 
on
ly
 c
on
du
ct
ed
 w
he
n 
th
e 
om
ni
bu
s 
A
N
OV
A
 w
as
 s
ig
ni
fic
an
t.
PA
S 
= 
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
 S
ub
gr
ou
p;
 D
SS
 =
 D
iso
rg
an
iz
ed
 S
pe
ec
h 
Su
bg
ro
up
; I
H
S 
= 
Im
pa
ire
d 
H
yg
ie
ne
 S
ub
gr
ou
p
Schizophr Res. Author manuscript; available in PMC 2019 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ryan et al. Page 21
Ta
bl
e 
5
D
em
og
ra
ph
ic
s b
y 
Su
bg
ro
up
 fo
r t
he
 L
CC
A
 o
f t
he
 N
A
PL
S 
2 
D
at
as
et
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
 
Su
bg
ro
u
p 
(A
)
D
iso
rg
an
iz
ed
 S
pe
ec
h 
Su
bg
ro
u
p 
(B
)
Im
pa
ir
ed
 H
yg
ie
ne
 
Su
bg
ro
u
p 
(C
)
O
dd
 a
nd
 E
ut
hy
m
ic
 
Su
bg
ro
u
p 
(D
)
D
ist
re
ss
ed
 a
nd
 
Av
o
lit
io
na
l S
ub
gr
o
u
p 
(E
)
To
ta
l
N
 (%
 of
 to
tal
)
41
3 
(56
%)
13
4 
(18
%)
12
0 
(16
%)
40
 (5
%)
30
 (4
%)
73
7
%
 F
em
al
e
43
%
38
%
43
%
58
%
40
%
43
%
A
ge
18
.6
18
.4
18
.2
18
.3
20
.5
18
.5
 (4
.3)
Fa
th
er
’s
 E
du
ca
tio
n 
(S
D)
6.
2
6.
3
6.
3
6.
4
6.
1
6.
2 
(1.
7)
M
ot
he
r’s
 E
du
ca
tio
n 
(S
D)
*
6.
1
6.
8A
6.
4
6.
7A
6.
2
6.
3 
(1.
6)
%
 L
at
in
o
22
%
15
%
13
%
18
%
13
%
18
%
%
 N
at
iv
e 
A
m
er
ic
an
 a
nd
 F
irs
t N
at
io
ns
2%
3%
2%
0%
0%
2%
%
 A
sia
n
7%
9%
6%
8%
13
%
7%
%
 B
la
ck
17
%
13
%
13
%
13
%
13
%
15
%
%
 O
th
er
5%
4%
6%
3%
7%
5%
%
 W
hi
te
55
%
58
%
64
%
67
%
60
%
58
%
%
 N
at
iv
e 
H
aw
ai
ia
n 
an
d 
Pa
ci
fic
 Is
la
nd
er
0%
1%
0%
0%
0%
0%
%
 M
ul
tir
ac
ia
l
14
%
13
%
10
%
10
%
7%
13
%
A
PS
*
*
92
%
E
90
%
E
98
%
A
BD
E
90
%
77
%
92
%
G
RD
*
*
*
10
%
16
%
C
7%
5%
33
%
A
BC
D
11
%
B
IP
S
2%
3%
2%
5%
7%
3%
Y
SP
D
*
*
*
6%
20
%
A
CE
8%
13
%
3%
9%
Li
fe
tim
e 
M
oo
d-
sta
bi
liz
er
*
*
*
6%
12
%
A
14
%
A
27
%
A
B
10
%
9%
Co
nv
er
sio
n*
11
%
20
%
A
CD
11
%
5%
17
%
13
%
*
=
 p
 <
 .0
5,
*
*
=
 p
 <
 .0
1,
*
*
*
=
 p
 <
 .0
01
N
ot
e:
 L
et
te
rs
 n
ex
t t
o 
a 
va
lu
e 
in
di
ca
te
 th
e 
ot
he
r s
ub
gr
ou
ps
 w
hi
ch
 th
at
 v
al
ue
 w
as
 s
ig
ni
fic
an
tly
 la
rg
er
 th
an
 a
cc
or
di
ng
 to
 p
os
t h
oc
 u
nc
or
re
ct
ed
 p
ai
rw
ise
 Z
 o
r T
 te
sts
. P
ai
rw
ise
 c
om
pa
ris
on
s w
er
e 
on
ly
 c
on
du
ct
ed
 
w
he
n 
th
e 
om
ni
bu
s 
A
N
OV
A
, χ
2 ,
 
o
r 
K
ap
la
n-
M
ei
r t
es
ts 
w
as
 s
ig
ni
fic
an
t.
A
PS
 =
 A
tte
nu
at
ed
 P
sy
ch
os
is 
Sy
nd
ro
m
e;
 G
RD
 =
 G
en
et
ic
 R
isk
 a
nd
 D
et
er
io
ra
tio
n 
Sy
nd
ro
m
e;
 B
IP
S 
= 
Br
ie
f I
nt
er
m
itt
en
t P
sy
ch
os
is 
Sy
nd
ro
m
e;
 Y
SP
D
 =
 Y
o
u
th
 a
nd
 S
ch
iz
ot
yp
al
 P
er
so
na
lit
y 
D
iso
rd
er
 S
yn
dr
om
e
Schizophr Res. Author manuscript; available in PMC 2019 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ryan et al. Page 22
Ta
bl
e 
6
A
N
OV
A
 o
f t
he
 L
CC
A
 D
er
iv
ed
 N
A
PL
S 
2 
Su
bg
ro
up
 S
ym
pt
om
 R
at
in
gs
PA
S 
(S
D)
 (A
)
D
SS
 (S
D)
 (B
)
IH
S 
(S
D)
 (C
)
O
ES
 (S
D)
 (D
)
D
A
S 
(S
D)
 (E
)
To
ta
l
P
Et
a 
2
U
nu
su
al
 Id
ea
s
3.
3 
(1.
3)E
3.
6 
(1.
1)A
 E
3.
4 
(1.
4)E
3.
4 
(1.
2)E
2.
5 
(2)
3.
3 
(1.
3)
=
.0
01
.
02
Su
sp
ic
io
us
ne
ss
2.
8 
(1.
6)
2.
9 
(1.
4)
2.
7 
(1.
4)
2.
7 
(1.
6)
2.
7 
(1.
7)
2.
8 
(1.
5)
=
.7
8
.
00
G
ra
nd
io
sit
y
1 
(1.
3)
1.
3 
(1.
5)A
 C
 D
 E
0.
8 
(1.
2)
0.
8 
(1)
0.
6 
(1.
2)
1 
(1.
3)
=
.0
04
.
02
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
3.
2 
(1.
5)E
2.
9 
(1.
5)E
3.
1 
(1.
5)E
3.
1 
(1.
4)E
2.
3 
(1.
6)
3.
1 
(1.
5)
<
.0
5
.
01
D
iso
rg
an
iz
ed
 S
pe
ec
h
1.
5 
(1.
4)
2.
5 
(1.
5)A
 C
 D
 E
1.
7 
(1.
3)
1.
6 
(1.
1)
1.
3 
(1.
4)
1.
7 
(1.
5)
<
.0
01
.
06
So
ci
al
 A
nh
ed
on
ia
2 
(1.
7)
3.
2 
(1.
7)A
 C
 D
2.
4 
(1.
7)A
2.
1 
(1.
4)
3.
3 
(1.
5)A
 C
 D
2.
4 
(1.
7)
<
.0
01
.
08
Av
o
lit
io
n
2.
2 
(1.
6)D
3.
1 
(1.
5)A
 D
2.
7 
(1.
5)A
 D
1.
2 
(1.
1)
4.
1 
(1.
1)A
 B
 C
 D
2.
4 
(1.
6)
<
.0
01
.
12
D
cr
 E
xp
re
ss
io
n 
of
 E
m
ot
io
n
1.
1 
(1.
4)
2.
5 
(1.
7)A
 C
 D
 E
1.
1 
(1.
3)
1 
(1.
2)
1.
5 
(1.
4)
1.
4 
(1.
5)
<
.0
01
.
13
D
cr
 E
xp
er
ie
nc
e 
of
 E
m
ot
io
n
1.
5 
(1.
6)
2.
3 
(1.
7)A
 D
 E
2.
2 
(1.
8)A
 D
 E
1.
4 
(1.
2)
1.
3 
(1.
4)
1.
7 
(1.
7)
<
.0
01
.
05
D
cr
 Id
ea
tio
na
l R
ic
hn
es
s
1.
1 
(1.
3)D
1.
6 
(1.
5)A
 C
 D
 E
1 
(1.
2)D
0.
5 
(0.
7)
1 
(1.
4)
1.
2 
(1.
3)
<
.0
01
.
04
O
cc
up
at
io
na
l F
un
ct
io
ni
ng
2.
7 
(2)
D
3.
5 
(1.
8)A
 C
 D
2.
8 
(2)
D
0.
7 
(1)
4.
5 
(1.
6)A
 B
 C
 D
2.
8 
(2)
<
.0
01
.
11
O
dd
 b
eh
av
io
r/a
pp
ea
ra
nc
e
0.
4 
(0.
8)
2.
4 
(1.
3)A
 C
 D
 E
0.
3 
(0.
6)
1.
6 
(1.
4)A
 C
 E
0.
8 
(1.
1)A
 C
0.
8 
(1.
2)
<
.0
01
.
40
B
iz
ar
re
 T
hi
nk
in
g
0.
8 
(1.
1)C
1.
6 
(1.
4)A
 C
 E
0.
5 
(0.
9)
1.
2 
(1.
3)C
0.
8 
(0.
9)
0.
9 
(1.
2)
<
.0
01
.
07
Tr
o
u
bl
e 
Fo
cu
s/A
tte
nt
io
n
2.
6 
(1.
3)D
2.
9 
(1.
4)A
 D
2.
8 
(1.
2)D
1.
8 
(1.
2)
2.
8 
(1)
D
2.
6 
(1.
3)
<
.0
01
.
03
Im
pa
ire
d 
Pe
rs
on
al
 H
yg
ie
ne
0 
(0)
2.
3 
(1.
3)A
 C
 D
 E
1.
7 
(0.
9)A
 D
0 
(0)
1.
7 
(1)
A
 D
0.
8 
(1.
2)
<
.0
01
.
66
Sl
ee
p 
D
ist
ur
ba
nc
e
2.
2 
(1.
6)
2.
5 
(1.
4)A
 D
2.
5 
(1.
5)A
 D
1.
7 
(1.
5)
3.
2 
(1.
2)A
 B
 C
 D
2.
3 
(1.
6)
<
.0
01
.
03
D
ys
ph
or
ic
 M
oo
d
3.
1 
(1.
7)D
3.
6 
(1.
4)A
 D
3.
7 
(1.
4)A
 D
2.
4 
(1.
6)
4.
2 
(1.
3)A
 D
3.
3 
(1.
6)
<
.0
01
.
05
M
ot
or
 D
ist
ur
ba
nc
e
0.
7 
(1)
1.
2 
(1.
3)A
 C
0.
9 
(1)
A
0.
9 
(1)
0.
9 
(1)
0.
8 
(1.
1)
<
.0
01
.
04
Im
p 
To
lr 
to
 S
tre
ss
2.
5 
(1.
9)D
2.
9 
(1.
9)A
 D
2.
9 
(1.
9)D
1.
8 
(1.
7)
4.
5 
(1)
A
 B
 C
 D
2.
7 
(1.
9)
<
.0
01
.
06
N
ot
e:
 G
re
y 
lin
es
 se
pa
ra
te
 p
os
iti
v
e 
do
m
ai
n 
sc
or
es
, n
eg
at
iv
e 
do
m
ai
n 
sc
or
es
, d
iso
rg
an
iz
ed
 d
om
ai
n 
sc
or
es
, a
nd
 g
en
er
al
 d
om
ai
n 
sc
or
es
 re
sp
ec
tiv
el
y.
 
Le
tte
rs
 in
di
ca
te
 th
e 
su
bg
ro
up
s t
ha
t w
er
e 
lo
w
er
 o
n
 th
e 
re
sp
ec
tiv
e 
sy
m
pt
om
. P
ai
rw
ise
 c
om
pa
ris
on
s w
er
e 
on
ly
 c
on
du
ct
ed
 w
he
n 
th
e 
om
ni
bu
s 
A
N
OV
A
 w
as
 s
ig
ni
fic
an
t.
PA
S 
= 
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
 S
ub
gr
ou
p;
 D
SS
 =
 D
iso
rg
an
iz
ed
 S
pe
ec
h 
Su
bg
ro
up
; I
H
S 
= 
Im
pa
ire
d 
H
yg
ie
ne
 S
ub
gr
ou
p;
 O
ES
 =
 O
dd
 a
nd
 E
ut
hy
m
ic
 S
ub
gr
ou
p;
 D
A
S 
= 
D
ist
re
ss
ed
 a
nd
 A
v
o
lit
io
na
l S
ub
gr
ou
p
Schizophr Res. Author manuscript; available in PMC 2019 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ryan et al. Page 23
Ta
bl
e 
7
Cl
in
ic
al
 S
ym
pt
om
 R
at
in
gs
 th
at
 w
er
e 
M
os
t D
isc
rim
in
at
iv
e 
o
f C
H
R-
P 
Su
bg
ro
up
s A
cr
os
s L
CC
A
N
A
PL
S 
1
N
A
PL
S 
2
H
ea
le
y 
et
 a
l. 
(in
 Pr
es
s)
Va
lm
ag
gi
a 
et
 a
l. 
(20
13
)
1
Im
p 
Pe
rs
on
al
 H
yg
ie
ne
 (0
.67
)
Im
p 
Pe
rs
on
al
 H
yg
ie
ne
 (0
.66
)
D
ys
ph
or
ic
 m
oo
d 
(0.
44
)
Su
bje
cti
v
e 
M
ot
or
 F
un
ct
io
ni
ng
 (0
.94
)
2
Av
o
lit
io
n 
(0.
24
)
O
dd
 B
eh
av
io
r/A
pp
ea
ra
nc
e 
(0.
4)
Av
o
lit
io
n 
(0.
35
)
Av
o
lit
io
n/
A
pa
th
y 
(0.
33
)
3
D
cr
 E
xp
rs
n 
of
 E
m
ot
io
n 
(0.
22
)
D
cr
 E
xp
rs
n 
of
 E
m
ot
io
n 
(0.
13
)
Im
p 
To
le
ra
nc
e 
N
rm
 S
tre
ss
 (0
.3)
A
nh
ed
on
ia
 [D
cr 
Em
 E
xp
rn
c] 
(0.
32
)
4
D
cr
 E
m
ot
io
na
l E
xp
er
ie
nc
e 
(0.
22
)
Av
o
lit
io
n 
(0.
12
)
D
cr
 Id
ea
tio
na
l R
ic
hn
es
s (
0.2
9)
So
ci
al
 Is
ol
at
io
n 
[S
oc
ial
 A
nh
] (
0.3
2)
5
So
ci
al
 A
nh
ed
on
ia
 (0
.16
)
O
cc
up
at
io
na
l F
un
ct
io
ni
ng
 (0
.11
)
Sl
ee
p 
D
ist
ur
ba
nc
e 
(0.
29
)
Sb
j C
og
 C
hg
 [T
 w
/Fo
c 
A
tn
] (
0.2
8)
6
O
dd
 B
eh
av
io
r/A
pp
ea
ra
nc
e 
(0.
13
)
So
ci
al
 A
nh
ed
on
ia
 (0
.08
)
O
cc
up
at
io
na
l F
un
ct
io
ni
ng
 (0
.25
)
Su
bj 
Au
ton
om
ic 
fun
cti
on
ing
 (0
.27
)
7
D
cr
 Id
ea
tio
na
l R
ic
hn
es
s (
0.1
2)
B
iz
ar
re
 T
hi
nk
in
g 
(0.
07
)
Tr
bl
 w
/F
o
cu
s 
&
 A
ttn
 (0
.23
)
A
lo
gi
a 
[D
cr 
Id
 R
ich
ne
ss*
] (
0.2
4)
8
Tr
bl
 w
/F
o
cu
s 
&
 A
ttn
 (0
.09
)
D
iso
rg
an
iz
ed
 S
pe
ec
h 
(0.
06
)
O
dd
 B
eh
av
io
r o
r A
pp
ea
ra
nc
e 
(0.
2)
Im
pa
ire
d 
Ro
le
 F
un
ct
io
n 
(0.
23
)
9
Im
p 
To
le
ra
nc
e 
N
rm
 S
tre
ss
 (0
.09
)
Im
p 
To
le
ra
nc
e 
N
rm
 S
tre
ss
 (0
.06
)
So
ci
al
 A
nh
ed
on
ia
 (0
.16
)
D
ep
re
ss
io
n 
(0.
16
)
10
D
iso
rg
an
iz
ed
 S
pe
ec
h 
(0.
09
)
D
ys
ph
or
ic
 M
oo
d 
(0.
05
)
D
cr
 E
xp
 o
f E
m
ot
io
n 
(0.
16
)
To
le
ra
nc
e 
to
 N
or
m
al
 S
tre
ss
 (0
.16
)
11
O
cc
up
at
io
na
l F
un
ct
io
ni
ng
 (0
.09
)
D
cr
 E
xp
er
ie
nc
e 
of
 E
m
ot
io
n 
(0.
05
)
D
cr
 E
xp
er
ie
nc
e 
of
 E
m
ot
io
n 
(0.
15
)
A
nx
ie
ty
 (0
.15
)
12
M
ot
or
 D
ist
ur
ba
nc
es
 (0
.06
)
D
cr
 Id
ea
tio
na
l R
ic
hn
es
s (
0.0
4)
Im
p 
Pe
rs
on
al
 H
yg
ie
ne
(0.
09
)
D
iso
rg
an
iz
ed
 S
pe
ec
h 
(0.
12
)
13
D
ys
ph
or
ic
 M
oo
d 
(0.
06
)
M
ot
or
 D
ist
ur
ba
nc
e 
(0.
04
)
Su
sp
ic
io
us
ne
ss
 (0
.08
)
Su
bj 
Em
oti
on
al 
Di
stu
rba
nc
es 
(0.
12
)
14
Su
sp
ic
io
us
ne
ss
 (0
.05
)
Tr
bl
 w
/F
o
cu
s 
&
 A
ttn
 (0
.03
)
M
ot
or
 D
ist
ur
ba
nc
e 
(0.
08
)
O
bs
er
ve
d 
Bl
un
te
d 
A
ffe
ct
 (0
.11
)
15
B
iz
ar
re
 T
hi
nk
in
g 
(0.
04
)
Sl
ee
p 
D
ist
ur
ba
nc
e 
(0.
03
)
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
 (0
.07
)
U
nu
su
al
 T
ho
ug
ht
 C
on
te
nt
 (0
.1)
16
G
ra
nd
io
sit
y 
(0.
02
)
U
nu
su
al
 Id
ea
s (
0.0
2)
D
iso
rg
an
iz
ed
 S
pe
ec
h 
(0.
06
)
A
gg
re
ss
io
n 
(0.
1)
17
Sl
ee
p 
D
ist
ur
ba
nc
e 
(0.
02
)
G
ra
nd
io
sit
y 
(0.
02
)
U
nu
su
al
 Id
ea
s (
0.0
5)
Su
bje
cti
v
e 
B
od
ily
 S
en
sa
tio
ns
 (0
.1)
18
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
 (0
.02
)
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
 (0
.01
)
B
iz
ar
re
 T
hi
nk
in
g 
(0.
02
)
O
CD
 (0
.08
)
19
U
nu
su
al
 Id
ea
s (
0)
Su
sp
ic
io
us
ne
ss
 (0
)
G
ra
nd
io
sit
y 
(0)
D
iss
oc
ia
tiv
e 
Sy
m
pt
om
s (
0.0
6)
20
O
bje
cti
v
e 
Co
gn
iti
v
e 
Ch
an
ge
s (
0.0
5)
21
D
iso
rg
, O
dd
, S
tig
m
 B
hv
r (
0.0
5)
22
O
bs
er
ve
d 
In
ap
pr
op
ria
te
 A
ffe
ct
 (0
.04
)
23
M
oo
d 
Sw
in
gs
 (0
.04
)
24
M
an
ia
 (0
.03
)
25
Su
ic
id
al
ity
 a
nd
 S
el
f-h
ar
m
 (0
.03
)
26
Pe
rc
ep
tu
al
 A
bn
or
m
al
iti
es
 (0
)
N
ot
e:
 N
um
be
rs
 a
fte
r N
A
PL
S 
sy
m
pt
om
s a
re
 η2
 
v
al
ue
s. 
N
um
be
rs
 a
fte
r H
ea
le
y 
et
 a
l. 
an
d 
Va
lm
ag
gi
a 
et
 a
l. 
ar
e 
R2
.
 
Sy
m
pt
om
 n
am
es
 in
 b
ra
ck
et
s 
un
de
r V
al
m
ag
gi
a 
et
 a
l. 
(20
13
) a
re
 S
IP
S 
sy
m
pt
om
 ra
tin
gs
 th
at
 
w
er
e 
co
n
sid
er
ed
 e
qu
iv
al
en
t f
or
 th
is 
co
m
pa
ris
on
. H
ig
hl
ig
ht
in
g 
is 
us
ed
 to
 e
m
ph
as
iz
e 
sy
m
pt
om
s t
ha
t r
ep
ea
te
d 
ac
ro
ss
 li
sts
Schizophr Res. Author manuscript; available in PMC 2019 June 23.
